SAN FRANCISCO — The fee-shifting storm clouds are continuing to gather over Gilead Sciences Inc.’s patent dispute with Merck & Co.
Merck asked U.S. District Judge Beth Labson Freeman on Tuesday to reject Gilead’s demand for a whopping $15.5 million in “exceptional case” attorney fees. No fees should be awarded until Gilead agrees to produce its flat-fee agreement with Fish & Richardson, Merck argued. Or alternatively, the company said, Fish should be ordered to produce a more detailed breakdown of its billings.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
